Adrenoleukodystrophy (ALD) is the most disabling form of hereditary nerve disease. Symptoms of Adrenoleukodystrophy include weakness, muscle cramps, urinary frequency, or flow, decreased appetite, fatigue, insomnia, urinary retention, depression, irritability, decreased sex drive, and hyperactive behavior. Symptoms can also occur in unaffected children. Onset can usually be seen when suddenly healthy, normal young boys suddenly start to regress.
There are several theories about what causes this form of diabetes. One of the theories suggests that the weakness of the ventricle, a portion of the heart's pump, causes the onset of adrenoleukodystrophy because the ventricular pump has been unable to maintain an adequate blood supply for the muscle tissues responsible for pumping blood to the rest of the body. The weakness of the ventricular muscle can result in decreased cardiac output due to decreased filtration of the blood by the ventricle and increased blood flow to the liver, kidneys, pancreas, and muscle tissues around the hip joint. Kidney disease can cause a decrease infiltration of the blood, resulting in the decrease of urine output, decreased levels of growth hormone, and loss of strength.
Adrenoleukodystrophy is a very rare genetic issue that is characterized by several symptoms such as the early onset of adrenomyeloneuropathy, Addison disease, and ALD. Depending upon these symptoms, the type of an adrenoleukodystrophy drug needs to be evaluated along with prescribing accurate treatment. This is the main factor that is driving the growth of the global adrenoleukodystrophy drug market. For instance, in May 2020, SwanBio Therapeutics, which a developer of biological treatments, announced that they have successfully raised around US$ 52 million for the treatment advancement of their viral-based gene therapy for adrenomyeloneuropathy. Key market players are also focusing on developing new treatments for treating this condition, which is also enhancing the growth of the global adrenoleukodystrophy drug market.
There is presently no treatment for adrenoleukodystrophy, although doctors are working on drugs that can slow down the progress of the disease and allow it to be controlled. Doctors often want to wait and see how the disease progresses before they make a decision to perform surgery. However, the side effects of the stem cell transplant treatments that are used to treat these health issues are the main restraining factor that is obstructing the growth of the global adrenoleukodystrophy drug market.
Owing to the prevalence of biotechnology labs in the region, North America is experiencing high demand in the global adrenoleukodystrophy drug market. For instance, according to Seed Scientific, there are over 6653 biotech companies in the United States. Moreover, the high investments in the biotechnology sector are also propelling the growth of the market. Owing to these factors, there have been several developments in the global adrenoleukodystrophy drug market. For instance, in January 2020, Minoryx Therapeutics received approval for its drug troglitazone (MIN-102), which helps treating x- adrenoleukodystrophy issues.